Bloom Syndrome and a BLM Carrier Result: What the Research Actually Shows

Bloom Syndrome and a BLM Carrier Result: What the Research Actually Shows

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

Bottom line: A consumer report that flags one changed copy of the BLM gene describes a carrier, not a patient. GeneReviews says it twice on one page: carriers, meaning people with one changed copy, “are not at risk of developing BSyn”, which is its short form for Bloom syndrome. Lab work backs that up. In the first counts, made in 1974, cells from people with Bloom syndrome swapped DNA between paired chromosome copies 89.0 times per metaphase, that is, per dividing cell. Carriers had normal rates. Every cancer number in this article that comes from the Bloom Syndrome Registry describes people with two pathogenic BLM variants. What a carrier result does raise is a question about a future pregnancy, and that question has a written-down number as its answer.

What you’ll learn

• Why one broken DNA-unwinding enzyme explains the disease, and why carriers test out as normal
• The real per-pregnancy math, and why the published carrier rate is a range
• What the Bloom Syndrome Registry recorded in 290 people with two pathogenic BLM variants
• What the 2024 update from the American Association for Cancer Research (AACR) changed, and what US and Canadian law protects

Bloom syndrome starts with one broken enzyme, not with a symptom list

Most pages about Bloom syndrome open with a photo and a symptom list. The mechanism explains that list better than the list explains itself.

The BLM gene sits on chromosome 15, at 15q26.1. It holds the recipe for the BLM helicase, a protein that works in a team with DNA topoisomerase III-alpha and RMI. Helicases unwind the DNA double helix. MedlinePlus Genetics calls the RecQ family they belong to the “caretakers of the genome”.

Mammals have five RecQ-like helicases. Three of them are tied to human disease: BLM in Bloom syndrome, WRN in Werner syndrome, and RECQL4 in Rothmund-Thomson syndrome. The 2024 AACR paper splits the protein’s job in three. It unwinds double-stranded DNA into single strands. It holds down extra swaps between paired chromosome copies while DNA is being copied. And it helps mend breaks that cut both strands.

Think of a rope-untangling machine on a production line. It keeps strands running free, and it stops two matching ropes from being spliced into each other. Take it out and both jobs fail at once.

The fingerprint you can count under a microscope

When both copies of BLM are broken, swapping between the two matching sister chromatids runs unchecked. That swap has a name: sister-chromatid exchange, or SCE. Labs count SCEs in a cell caught in the act of splitting, a stage called metaphase. So the damage becomes a number you can count.

• People with Bloom syndrome: a mean of 40 to 100 SCEs per metaphase, against fewer than 10 in cells from people without the disease.
• The first dataset, from 1974: normal white blood cells averaged 6.9 SCEs per metaphase (range 1 to 14). Cells from people with Bloom syndrome averaged 89.0 (range 45 to 162).
• Carriers: normal SCE rates were measured in Bloom syndrome carriers in that same work. This was measured, not assumed.
• MedlinePlus puts the same finding in plain terms for affected people: SCE runs about 10 times higher than normal.
• Labs that read chromosomes also look for a four-armed chromosome shape called a quadriradial. StatPearls and the Bloom Syndrome Registry both name it as a hallmark in affected people.

One warning belongs here. High SCE counts are not unique to Bloom syndrome. Faults in RMI1, RMI2 and TOP3A raise them too, and GeneReviews says high SCEs alone are not enough to confirm the diagnosis.

What the disease looks like in people who have it

All of the figures below describe people with two pathogenic BLM variants, not carriers.

• Very poor growth before and after birth. Mean adult height is 149 cm in men (range 128 to 164 cm) and 138 cm in women (range 115 to 160 cm).
• A sun-driven red rash across the cheeks and nose, which StatPearls likens to the rash of lupus.
• A mild weak spot in the immune system. Long-term lung trouble goes with it, which is why GeneReviews asks for a lung check at every visit.
• Early diabetes, driven by a body that stops answering insulin. It was found in 51 of 294 people in the Bloom Syndrome Registry, or 17.3%, at a mean age of 26.2 years (range 4 to 48 years).
• Low sex-hormone output and reduced fertility. Even so, 11 women with Bloom syndrome followed in the registry have been pregnant at least once, and seven gave birth to 11 healthy babies of normal size.

That list is the point of difference. Bloom syndrome is a whole-body disease of an unstable genome, and it causes cancer. It is not a cancer syndrome that also makes people short. If this sounds like someone in your family rather than a line on a carrier report, see a medical geneticist.

Section recap: One missing DNA-unwinding enzyme leaves a fingerprint you can count: 40 to 100 SCEs per metaphase in affected people, against fewer than 10 in healthy cells. Carriers were measured and came out normal.

Autosomal recessive inheritance, and what the consumer report actually tested

The first fear deserves the first line. A carrier has one non-working and one working copy of BLM. GeneReviews says carriers are not at risk of getting Bloom syndrome. MedlinePlus says the same about recessive traits in general. The parents of an affected child each carry one copy and usually show no signs at all. The disease needs two non-working copies, one from each birth parent.

The arithmetic, and the trap inside it

The NIH Genetic and Rare Diseases Information Center puts the numbers plainly. If both birth parents are carriers, each child has a 25% chance of getting both broken copies and having the disease. There is also a 50% chance the child gets one copy and is a carrier. GeneReviews gives the same split for the brothers and sisters of an affected child: 25% affected, 50% carrier, 25% neither.

• The dice are thrown fresh at each conception. A healthy first child changes nothing about the next pregnancy.
• The same-gene rule. Both parents must carry a change in BLM. A BLM carrier whose partner carries a change in some other recessive gene faces no added Bloom syndrome risk from that match.
• The 25% figure holds only once both partners are known BLM carriers. Before that, the honest number is much smaller. The next section works it out.
• Carrier status is not a health finding for the carrier. It is a finding about future pregnancies.

What the 23andMe carrier report tested

The scope of that test is on the public record. The US Food and Drug Administration (FDA) granted De Novo classification DEN140044 to the 23andMe Personal Genome Service on 19 February 2015. The grant sits under regulation 21 CFR 866.5940, product code PKB. Bloom syndrome carrier status was the first carrier test sold straight to buyers that the FDA authorized.

The FDA Decision Summary states the use plainly. The test spots the BLMAsh change in the BLM gene. It can be used to work out carrier status in adults of childbearing age, but it “cannot determine if a person has two copies of the BLMAsh variant”.

You will meet the same change written three ways while searching. All three name one change.

Style	How it is written	Source
Current naming	c.2207_2212delinsTAGATTC, protein p.Tyr736LeufsTer5	GeneReviews
Other spelling	c.2281delATCTGAinsTAGATTC, p.(Tyr736fs)	AACR 2024
Legacy / plain words	2281del6ins7, or blmAsh: six DNA letters cut out and seven put in at spot 2281	MedlinePlus, FDA

Two more points follow from the FDA record. The agency’s own special control says the test does not spot every gene change tied to Bloom syndrome. A change that was not tested may still be there, and may still cause disease. The rule also makes the maker tell buyers how to reach a board-certified clinical molecular geneticist for counseling. Take that offer up, or ask your primary care doctor for a referral.

Why ancestry is not destiny here

The blmAsh change is a founder variant, meaning one change handed down to a whole group from a shared ancestor long ago. But it is not one founder’s alone. Ellis and colleagues found it on 58 of 60 chromosomes passed by Ashkenazi parents to children with Bloom syndrome. Among 91 unrelated non-Ashkenazi people with the disease, it turned up in 5. All 5 came from Spanish-speaking Christian families in the southwestern United States, Mexico or El Salvador.

The pattern of DNA markers around the gene points to two separate founder events. A later survey of 134 affected people in the registry found 64 different BLM changes in 125 of them. A partner of any ancestry can carry a BLM change that a one-change screen cannot see.

Section recap: Carriers are not affected, and the disease needs two pathogenic BLM variants, one from each birth parent. The consumer report is an FDA-authorized screen for one founder change, and it cannot read the rest of the gene.

How common the change is, and the honest number for a pregnancy

The published carrier rate for blmAsh, also called the carrier frequency, is a spread rather than one point. Melting the studies into a single number to remember is how accuracy gets lost.

Study or source	Group sampled	Carrier rate reported
Li et al. 1998	1,491 Ashkenazi Jewish people, no known Bloom syndrome in the family	1 in 107
Shahrabani-Gargir et al. 1998	1,613 Ashkenazi Jews in Israel	1 in 101 (16 carriers); 0 of 552 non-Ashkenazi people
Shahrabani-Gargir et al. 1998, subgroup	Ashkenazi Jews with two parents of Polish descent	1 in 37
Roa et al. 1999	1,016 Ashkenazi Jewish samples, US	0.98%, about 1 in 102; pooled with earlier data, about 1 in 104
Cunniff et al. 2017 review	Pooled across studies	average 1 in 110; as high as 1 in 45 among Jews from Poland
GeneReviews 2023, citing Fares et al. 2008	Ashkenazi Jews living in the United States	1 in 157
GeneReviews 2023, citing Peleg et al. 2002	Ashkenazi Jews living in Israel	1 in 111

Two things are worth noticing. The 1998 to 1999 first-hand studies cluster near 1 in 100, while the two numbers GeneReviews carries in 2023 are lower. And where a family came from inside the Ashkenazi world moves the number a long way.

For people with no Ashkenazi roots there are two anchors. Shahrabani-Gargir found no carriers among 552 non-Ashkenazi people. In the broad ExAC gene database, BLM changes that cut the protein short show up on about 9 of every 10,000 chromosomes. That works out to roughly 1 carrier in 550 people, which is an estimate rather than a measured rate.

Putting it together for one pregnancy

The table below takes a known carrier’s 50% chance of passing the change on, and multiplies it by the partner’s chance of carrying a BLM change. Treat every row but the first as an estimate, and take it to a genetic counselor before you act on it.

Partner situation	Chance the partner carries a BLM change	Chance per pregnancy of Bloom syndrome
Partner is a known BLM carrier	Certain	25%, or 1 in 4
Partner has Ashkenazi roots, not yet tested	roughly 1 in 101 to 1 in 157	roughly 1 in 400 to 1 in 630
Partner has no Ashkenazi roots, not yet tested	roughly 1 in 550, from the ExAC-based estimate	roughly 1 in 2,200, under 0.05%
Partner tested negative on a panel that read all of BLM	much reduced, never zero	far below 1 in 2,200

The disease itself stays rare in every group. Bloom syndrome shows up in about 1 in every 48,000 babies born to Ashkenazi Jewish parents. MedlinePlus says only a few hundred affected people have been written up, about a third of them of Ashkenazi Jewish background. At the 2023 GeneReviews update, 294 people were known to the Bloom Syndrome Registry worldwide.

Why an ultra-rare disease sits on a mass-market panel

The American College of Medical Genetics and Genomics (ACMG) marks off what it calls tier 3 carrier screening with a cut-off. It covers conditions carried by 1 in 200 people or more in any ethnic group with a fair share of the US population. Its 2021 practice resource says every pregnant patient, and everyone planning a pregnancy, should be offered tier 3 screening. In all it lists 97 recessive genes.

BLM did not clear the bar on general population data. ACMG says the rates in the gnomAD gene database put BLM below 1 in 200. BLM went on the list because it is known to reach at least 1 in 200 in the Ashkenazi Jewish group. GeneReviews notes that Bloom syndrome sits on most expanded carrier panels.

ACMG adds a line that matters for mixed-ancestry couples. Limiting carrier screening by social ideas of ethnic group, or by the ancestry people claim for themselves, is “both inequitable and scientifically flawed”. Ask an obstetric provider or genetic counselor for the panel’s full gene list.

Section recap: The published blmAsh carrier rate runs from about 1 in 101 to 1 in 157 in Ashkenazi groups. Polish-descent estimates sit near 1 in 37 to 1 in 45. Only two known BLM carriers make a 25% per-pregnancy risk.

The cancer numbers from the Bloom Syndrome Registry, and whose numbers they are

These numbers exist because of one long-running group of patients. The Bloom Syndrome Registry at Weill Cornell Medicine gathers clinical data and samples from affected people, to map how the disease plays out over a life. Its list of papers starts with James German’s 1969 write-up of the first 27 patients.

The 2022 analysis in Genetics in Medicine is the reference dataset. Every number below describes people with two pathogenic BLM variants, not carriers.

Finding in the Bloom Syndrome Registry group	Number reported
Members studied	290 people with Bloom syndrome
Had at least one cancer	155 people, or 53%
Total cancers recorded	251
Had exactly one cancer	100 of the 155, or 65%
Had more than one separate cancer	55 of the 155, or 35%
Blood cancers	83 of 251, or 33%
Solid tumours	168 of 251, or 67%
Chance of having had a cancer by age 40 (cumulative incidence)	83%
Median survival, all members	36.2 years

Leukaemia and lymphoma together were more common than any single type of solid tumour. The solid tumours seen most often were colorectal, breast, and mouth and throat.

One number needs careful handling. GeneReviews lists 30 colorectal tumours in its tumour table, at a median age of 36 years when found, and a range of 16 to 49 years. That is 30 of the 251 recorded tumours, not a lifetime colorectal risk per patient. No source here supports quoting one.

The analysis also found no real difference in time to first cancer, or in survival, by genotype. No mix of gene changes lets anyone read one person’s outlook off a lab report. That is one more reason these talks belong with an oncologist or a medical geneticist.

The boundary, stated once and clearly

• 53%, 35%, 83% and 36.2 years are numbers for people with two pathogenic BLM variants signed up to the Bloom Syndrome Registry. A person with one BLM change is not in that group.
• GeneReviews says flatly that carriers are not at risk of getting Bloom syndrome.
• The registry pattern is cancer that arrives early, and often comes back as a new one in the same person. That is the clinical face of a genome that cannot mend itself.

Section recap: Among 290 Bloom Syndrome Registry members with the disease, 155 (53%) had 251 cancers. The estimated risk of having had a cancer by age 40, the cumulative incidence, reached 83%. Those numbers belong to people with two pathogenic BLM variants.

Confirming the result: screening tests, partner testing, and a real diagnosis

Three different tests get blurred together on content-farm pages. They answer three different questions.

Step 1: the direct-to-consumer report is a screen

• The FDA files the device as Class II with special controls, for carrier screening in adults of childbearing age.
• The buyer warning that the FDA requires is blunt. The test is “not intended to diagnose a disease”. It is also not meant to say anything about the health of an unborn baby, or about a newborn’s later risk.
• The rule makes the report itself carry two warnings. A positive result may wrongly label someone a carrier when the predictive value for a group runs between 5% and 50%. It is very likely to be wrong when that value falls under 5%.
• The FDA also records that a sample can fail in the lab up to 7.6% of the time.
• Any result that will drive a pregnancy or medical choice should be run again in a CLIA-certified lab in the US, or a provincially accredited lab in Canada. CLIA is the US law that sets quality rules for clinical labs. A doctor or genetic counselor orders that test.

Step 2: the partner’s test is the one that decides

For a couple, the partner’s result decides whether any Bloom syndrome risk exists at all.

• Ask for an expanded carrier panel that reads all of BLM, not a one-change founder screen. A survey of 134 affected people in the Bloom Syndrome Registry found 64 different BLM changes in 125 of them.
• ACMG says partners may be offered tier 3 screening, when it is done at the same time as their partner’s.
• A negative screen lowers risk without wiping it out. ACMG gives the left-over risk as the carrier rate in the group times one minus the detection rate.
• ACMG also asks labs to report the tier number and the full list of genes tested. Ask for that list.
• Timing matters during a pregnancy. Ask a genetic counselor early how the timing of partner testing shapes which choices stay open.

Step 3: testing someone who may really have Bloom syndrome

• The diagnosis rests on finding two pathogenic BLM variants on gene testing.
• GeneReviews treats SCE counting as a back-up test, used when only one BLM change is found. High SCE counts alone cannot settle the diagnosis.
• A blood test can mislead in a few affected people. Some stem cells switch back to the working sequence on their own, so high-SCE and normal-SCE cells sit side by side. The Bloom Syndrome Registry advises SCE studies on cultured skin cells when suspicion is strong but the blood test does not confirm it.

Where to find a counselor

• United States: the National Society of Genetic Counselors runs a search page at findageneticcounselor.nsgc.org.
• Canada: the Canadian Association of Genetic Counsellors links its public list at genetic-counsellors.ca, and provincial medical-genetics programmes are the other route in.
• Affected families: the 2024 AACR paper names the Bloom Syndrome Registry at Weill Cornell as the disease-specific family resource. The National Organization for Rare Disorders also keeps a Bloom syndrome page.

Section recap: A consumer carrier report is an FDA-authorized screening test that cannot diagnose, and cannot see the rest of the gene. Running it again in a clinical lab, and testing the partner on a panel that reads all of BLM, are the two steps that change the math.

Screening for people who have Bloom syndrome, and what changed in 2024

This section is for families with an affected member. It does not apply to carriers. Doctors call this kind of planned, repeated screening surveillance.

The standing disease-specific guideline is Cunniff and colleagues, in the American Journal of Medical Genetics Part A in 2018. Its authors built it from Bloom Syndrome Registry data, published papers and clinic know-how. They wrote that the advice can be revised as more is learned about how useful it proves. That is expert agreement, and the people who wrote it said so.

In July 2023 the AACR held its second Childhood Cancer Predisposition Workshop. The update came out in Clinical Cancer Research on 15 November 2024. It covers Bloom syndrome next to Fanconi anaemia, ataxia telangiectasia, Nijmegen breakage syndrome and other diseases of an unstable genome. It too is expert agreement, not trial data.

The 2024 update took two things away rather than adding them.

Target	GeneReviews 2023 schedule	2024 AACR update
Wilms tumour	Belly ultrasound every 3 months from diagnosis to age 8	Routine ultrasound no longer advised in the text, because reported Wilms tumour rates are 3%, in line with 2021 SIOP-Europe advice
Lymphoma	Whole-body MRI every 1 to 2 years from age 12 to 13	Routine whole-body MRI for lymphoma is not advised in children, for want of data to back it
Colorectal cancer	Colonoscopy once a year and a stool blood test every 6 months, from age 10 to 12	The narrative moved the colonoscopy start age earlier, from 15 to 10 to 12; Table 2 of the same paper says 12 to 13
Breast cancer	Breast MRI once a year in women from age 18	Breast MRI every year from age 18
Baseline care	Lung check at each visit; skin review each year after any odd-looking spot	At least one clinical check a year from diagnosis, plus teaching the family the signs of blood cancers and Wilms tumour
Prevention	Keep radiation as low as possible; MRI and ultrasound preferred where they work	Avoid radiation, protect from the sun, HPV shot, skin exam each year

Two honest caveats belong with that table. First, the 2024 paper contradicts itself. Its Table 2 still lists a belly ultrasound every 3 months to age 8 even though the text drops it, and the two colonoscopy start ages differ. Second, the earlier colonoscopy is meant to prevent, not to catch. The youngest colorectal cancer on record in Bloom syndrome was at age 16, and some patients grow polyps first, so taking polyps out early is thought to help. Gaps could be stretched for patients under 16 if the first colonoscopy is clear.

Bloom syndrome is not only a cancer disease, so GeneReviews also lists non-cancer checks for affected people:

• Fasting glucose and HbA1c once a year from age 10
• A blood fat, or lipid, panel once a year from age 10
• A thyroid blood test (TSH), with a follow-on thyroxine test if the first is off
• A lung check at every visit, given the long-term lung trouble
• Strict sun cover, plus a skin review after any odd-looking spot

None of this applies to a person with one BLM change. No source read here advises a change of screening on carrier status alone. A children’s cancer doctor or a medical geneticist runs this plan for an affected child.

Section recap: The 2024 AACR update dropped routine whole-body MRI and routine Wilms ultrasound, and moved the colonoscopy start age earlier, from 15 to 10 to 12. The paper also contradicts itself between text and table. The plan is for people with two pathogenic BLM variants only.

Treatment in 2026: no therapy for the root cause, and a rebuilt cancer protocol

No approved therapy that treats the root cause of Bloom syndrome, or cures it, could be found as of August 2026, from either the FDA or Health Canada. Read that as nothing found, rather than as proof that nothing exists. It rests on three checks.

• A ClinicalTrials.gov search for the condition returned only one study truly about this disease. That study is NCT00021437, watch-only rather than a treatment test, now finished, funded by the NIH National Center for Research Resources. Every other hit was an unrelated trial whose short name happens to be BLOOM.
• The “Therapies Under Investigation” part of GeneReviews names no drug at all, and warns that there may be no trials for this disease.
• A search of the Health Canada Drug Product Database turned up no Bloom syndrome product, and the FDA record shows none either.

Care is therefore supportive. Cunniff and colleagues put it directly: the treatments on offer for Bloom syndrome ease symptoms, and finding problems early has the potential to improve outcomes.

Why cancer treatment itself has to be rebuilt

Chemotherapy, or chemo, and radiation work by damaging DNA. Cells with no working BLM helicase cannot mend that damage properly. GeneReviews puts the result in its treatment table. Their cells are easily harmed by DNA-damaging drugs and by radiation. So people with Bloom syndrome usually take no more than half the standard chemo dose, with no sign of worse outcomes.

The same page says exposure to radiation should be kept as low as it can be. It also names MRI and ultrasound as the preferred scans where they will do the job. It adds that a drug class called alkylating agents, and radiation therapy, count as high risk and are avoided when possible. The 2024 AACR update backs lower doses of standard drug plans, paired with plans that leave alkylating agents out.

A French national series in Human Mutation in 2025 adds real, if small, clinical detail. It looked at nine children with Bloom syndrome and cancer. The median age when Bloom syndrome was found was 6 years, and the median age at cancer was 12 years. Six had solid tumours and three had blood cancers.

Reported dosing detail, children with Bloom syndrome	Source
Usually take no more than half the standard chemo dose	GeneReviews
Nephroblastoma, the tumour also called Wilms tumour, one child: doses cut by up to 30%	Pacaud et al. 2025
Bone cancer, one child: doses cut from the start by up to 50%	Pacaud et al. 2025
Rhabdoid tumour, one child: large dose cuts, by up to 70%	Pacaud et al. 2025
One child given a full dose on a standard leukaemia plan. Bone marrow that would not recover, steroid-driven diabetes, iron overload in the liver. Upkeep treatment cut short by more than a year	Pacaud et al. 2025
Radiation given without trouble to the 2 patients who had it, one of them a recorded 14.4 Gy to the left kidney bed	Pacaud et al. 2025

The paper’s one wider claim is careful, and so is the wording here: every patient who reached remission had had chemo doses cut to fit what they could take. Outcomes were mixed. Four patients relapsed and four died, one of them from the treatment itself, while five reached remission. The median age at death was 14.5 years (range 6 to 23). Problems ran to long spells of bone marrow failure, blood infection and treatment stopped early.

The radiation finding is truly new and truly small. The authors put it forward as a challenge to earlier thinking, and say the place of radiation is still unclear. Two patients is not a change in standard care.

The practical point is blunt. An oncologist who does not know a patient has Bloom syndrome may give a standard dose of a routine drug plan. That is a strong reason to confirm a suspected diagnosis in a clinical lab, and to carry the paperwork for it. Raise this with the treating oncologist and a medical geneticist together, before any protocol starts.

Section recap: No approved therapy for the root cause, and no registered treatment trial for Bloom syndrome, could be found as of August 2026. Cancer care in affected people uses much lower chemo doses and as little radiation as possible.

Carriers: the contested colorectal signal, family testing, and US and Canada law

A carrier’s own question is whether one BLM change raises their own cancer risk. The studies genuinely disagree, so this section reports both ways instead of picking one.

Two terms in the table below need unpacking first. An odds ratio compares how often carriers turn up in one group against another. An odds ratio reported as 2.34 means carriers showed up about twice as often among the cancer cases as among the healthy controls. Penetrance means how often people who carry a change go on to get the illness, so low penetrance means most of them never do.

Study	Design and sample, carriers	Result for carriers
Gruber et al. 2002, Science	Ashkenazi colorectal cancer cases and controls from New York and Israel; 1,244 cases and 10,099 controls, as reported in a later review	blmAsh in 1 in 54 colorectal cancer cases against 1 in 118 controls; odds ratio reported as 2.34, p = 0.0002
Cleary et al. 2003, Cancer Research	2,333 Jewish people, made up of 497 with colorectal cancer, 125 with polyps, 767 with other cancers and 944 controls	blmAsh carried by 0.80% with colorectal growths, 0.87% with any cancer, 0.85% of controls. No tie to age when found, to the number of tumours, or to cancer in the family
de Voer et al. 2015, Scientific Reports	185 early-onset colorectal cancer patients and 532 controls matched to the same group	3 patients (1.6%) against 1 control (0.2%) carried a known harmful BLM change. P = 0.055 in the main test, and P = 0.0035 against outside databases. The authors judge penetrance moderate to low

Three caveats keep this honest. The exact odds ratio and its range from the 2002 paper could not be checked at the source, and a published erratum exists. So “roughly a two-fold excess” is the safest reading. The 2015 gap, in plain counts, is three patients against one control. And the reason the question stays open is sample size. Cleary and colleagues worked out that ruling out an odds ratio of 1.3 would have needed 25,737 cases and 25,737 controls.

Other signals point both ways. GeneReviews notes higher carrier rates reported in mesothelioma, cancer of the womb lining, and colorectal cancer. It still says the cancer risk of carriers as a group is unclear. A 2017 review lists further studies as inconclusive, and notes a Slavic founder change tied to breast cancer but not to prostate or ovarian cancer.

What that means in practice today

The National Comprehensive Cancer Network (NCCN) weighed this question and took a clear stand. Two versions of its Genetic/Familial High-Risk Assessment guideline for colorectal cancer can be checked in public: Version 3.2017 and Version 2.2019. In both, the row for BLM heterozygotes, which is their word for carriers, is graded “Not well-established”. Risk is listed as “Uncertain – none to low”, with a note of possible added colorectal cancer risk. The Version 3.2017 update summary records that BLM carriers were dropped from the table that carries management advice.

• By contrast, the same guideline does give MUTYH carriers management advice, so “carrier of a recessive cancer gene” is not one flat category.
• What that means in those versions: a BLM carrier follows the same age-based colorectal screening as anyone else, unless personal or family history says otherwise.
• Whether the 2025 to 2026 NCCN versions still say this was not checked here, so read it as the most recent public wording rather than today’s release.
• Family history is the one thing that can change the answer. Bring it, in detail, to a genetic counselor or your primary care doctor.

Telling the family

Cascade testing means testing your blood relatives, and it is plain arithmetic. Suppose one parent carries the change and the other does not. Each full brother or sister then has about a 1 in 2 chance of carrying it, and each child of a carrier has about a 1 in 2 chance. GARD spells out the case where both parents carry it, 25% affected and 50% carrier; the one-parent numbers follow from the same rule of inheritance. That is useful for an adult relative who is planning a pregnancy. It matters most inside a founder group, where the partner’s chance of carrying the same change is higher.

For a healthy young child, the picture is different. Carriers are not at risk of getting Bloom syndrome, so a carrier result changes nothing about a child’s own health care. It bears on a pregnancy choice many years away. Whether and when to test a child is a question for a certified genetic counselor.

What US and Canadian law protects

Question	United States, GINA 2008	Canada, Genetic Non-Discrimination Act 2017
Health insurance	Protected. Covers private health insurers, Medicare, Medicaid, Federal Employees Health Benefits and the Veterans Health Administration	Covered in a roundabout way: no one may demand a genetic test or its results as a condition of a contract or service
Employment	Protected under Title II, enforced by the EEOC	The Act amends the Canada Labour Code and the Canadian Human Rights Act
Life, disability, long-term care insurance	Not covered by GINA; some states add cover	Covered. The Supreme Court’s own summary says insurance companies could not make people get tested to get life insurance
Small employers	GINA does not apply to employers with fewer than 15 staff	Not framed the same way
Military	TRICARE may not use genetic details for cover, underwriting or setting premiums, but GINA’s job protections do not apply to the US military	Not framed the same way
Penalties	Title I and Title II enforcement	Up to a $1,000,000 fine and 5 years on indictment; up to $300,000 and 12 months on summary conviction

A few details are worth spelling out. GINA counts family medical history as genetic information, alongside test results. Its health-insurance rules took effect on 7 December 2009, and its job rules on 10 January 2011. For the gap in life, disability and long-term-care cover, the NHGRI Genome Statute and Legislation Database lists state laws that may fill it.

The Canadian law bars anyone from making you take a genetic test, from making you hand over results, and from using results without written consent. It carves out doctors treating the person, and researchers working with volunteers, so a doctor can still ask. The Supreme Court of Canada upheld Parliament’s power to pass it in Reference re Genetic Non-Discrimination Act, 2020 SCC 17, on 10 July 2020.

Section recap: Whether one BLM change raises colorectal cancer risk is unsettled, and NCCN dropped BLM carriers from its management table in the versions that can be checked here. GINA protects US health insurance and jobs but not life, disability or long-term-care cover, while Canada’s law reaches insurance contracts head-on.

Frequently asked questions

Will I get Bloom syndrome, or cancer, because I carry one BLM variant?

You will not get Bloom syndrome. GeneReviews says carriers are not at risk of getting it, and carriers were measured with normal SCE rates. On cancer, the evidence is unsettled. One 2002 study found roughly a two-fold excess of colorectal cancer in Ashkenazi carriers. A 2003 study of 2,333 people found carrier rates of 0.80% in colorectal growths against 0.85% in controls. In the most recent versions open to the public, 3.2017 and 2.2019, NCCN grades the risk as uncertain, none to low, and gives no separate management advice.

Will my children inherit it?

Each child of a carrier has about a 1 in 2 chance of being a carrier too. A child can only have Bloom syndrome if both birth parents pass on a BLM change. If both parents are known carriers, that chance is 25% per pregnancy. If the partner is untested, the honest figure is far smaller, and it turns on ancestry. Testing the partner on a panel that reads all of BLM swaps the estimate for an answer.

Will this affect my health or life insurance?

In the US, GINA bars health insurers from using genetic details, and that cover reaches private insurers, Medicare, Medicaid, Federal Employees Health Benefits and the Veterans Health Administration. It does not reach life, disability or long-term-care insurance, though some states add cover. In Canada, the Genetic Non-Discrimination Act bars anyone from demanding a test or its results as a condition of a contract or service. The Supreme Court upheld it in 2020 SCC 17. Speak to a genetic counselor before you sign anything, if this is a live worry.

Can my employer find out?

GINA’s Title II bars employers from using genetic details, and the EEOC enforces it. Two gaps exist. Employers with fewer than 15 staff sit outside the law. And GINA’s job protections do not apply to the US military, which may use genetic and medical details in job choices. In Canada, the Act amends the Canada Labour Code and the Canadian Human Rights Act.

Should I get a second opinion or a confirming test?

Yes, before any choice. The FDA’s own terms say a consumer carrier report is not meant to diagnose, and that a positive result may wrongly label someone a carrier. The rule also makes the company explain how to reach a board-certified clinical molecular geneticist. Run the result again in a clinical lab, and find a counselor through the NSGC search page in the US, or genetic-counsellors.ca in Canada.

Summary

A BLM carrier flag on a consumer report is a finding about future pregnancies, not a health diagnosis.

• The mechanism explains the rest. Losing both copies of BLM drives 40 to 100 SCEs per metaphase, against fewer than 10 normally. Carriers were measured and came out normal.
• Carriers do not get the disease. It takes two pathogenic BLM variants, one from each birth parent.
• The registry numbers belong to affected people. Among 290 people with Bloom syndrome, 155 (53%) had 251 cancers. The estimated risk of having had a cancer by age 40, the cumulative incidence, reached 83%.
• The carrier rate is a range, from about 1 in 101 to 1 in 157 in Ashkenazi groups.
• Testing the partner is the step that decides, on a panel that reads all of BLM rather than one founder change.
• The 2024 AACR update dropped routine whole-body MRI and routine Wilms ultrasound, and moved the colonoscopy start age earlier, from 15 to 10 to 12.
• No approved therapy for the root cause was found as of August 2026, and cancer care uses much lower doses.
• The law differs by border. GINA leaves life, disability and long-term-care insurance uncovered; Canada’s law reaches insurance contracts head-on.

The next step for a carrier is short. Run the result again in a clinical lab, then test the partner on a panel that reads all of BLM. Book a genetic counselor to read both together.

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

References

1. Langer K, Cunniff CM, Kucine N. Bloom Syndrome. GeneReviews, University of Washington / NCBI Bookshelf NBK1398 (initial posting 2006-03-22; last update 2023-10-12). Bookshelf PMID 20301572. https://www.ncbi.nlm.nih.gov/books/NBK1398/
2. Sugranes TA, Flanagan M, Thomas C, Chang VY, Walsh M, Cunniff C (2022). Age of first cancer diagnosis and survival in Bloom syndrome. Genetics in Medicine 24(7):1476-1484. PMID 35420546; DOI 10.1016/j.gim.2022.03.008. https://pubmed.ncbi.nlm.nih.gov/35420546/
3. Nakano Y, Kuiper RP, Nichols KE, et al. (2024). Update on Recommendations for Cancer Screening and Surveillance in Children with Genomic Instability Disorders. Clinical Cancer Research 30(22):5009-5020. PMID 39264246; PMC11705613; DOI 10.1158/1078-0432.CCR-24-1098. https://pmc.ncbi.nlm.nih.gov/articles/PMC11705613/
4. Cunniff C, Djavid AR, Carrubba S, et al. (2018). Health supervision for people with Bloom syndrome. American Journal of Medical Genetics Part A 176(9):1872-1881. PMID 30055079; DOI 10.1002/ajmg.a.40374. https://pubmed.ncbi.nlm.nih.gov/30055079/
5. Pacaud C, Nazon C, Pages M, et al. (2025). Management of Paediatric Cancers Associated With Bloom Syndrome. Human Mutation 2025:7065233. PMID 40641635; PMC12245492; DOI 10.1155/humu/7065233. https://pmc.ncbi.nlm.nih.gov/articles/PMC12245492/
6. Gruber SB, Ellis NA, Scott KK, et al. (2002). BLM heterozygosity and the risk of colorectal cancer. Science 297(5589):2013. PMID 12242432; DOI 10.1126/science.1074399. Erratum: Science 2002;298(5594):751. https://pubmed.ncbi.nlm.nih.gov/12242432/
7. Cleary SP, Zhang W, Di Nicola N, et al. (2003). Heterozygosity for the BLM(Ash) mutation and cancer risk. Cancer Research 63(8):1769-1771. PMID 12702560. https://pubmed.ncbi.nlm.nih.gov/12702560/
8. de Voer RM, Hahn MM, Mensenkamp AR, et al. (2015). Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Scientific Reports 5:14060. PMID 26358404; PMC4566092; DOI 10.1038/srep14060. https://pubmed.ncbi.nlm.nih.gov/26358404/
9. Li L, Eng C, Desnick RJ, German J, Ellis NA (1998). Carrier frequency of the Bloom syndrome blmAsh mutation in the Ashkenazi Jewish population. Molecular Genetics and Metabolism 64(4):286-290. PMID 9758720 — with Shahrabani-Gargir L, et al. (1998). High frequency of a common Bloom syndrome Ashkenazi mutation among Jews of Polish origin. Genetic Testing 2(4):293-296. PMID 10464606 — and Roa BB, Savino CV, Richards CS (1999). Ashkenazi Jewish population frequency of the Bloom syndrome gene 2281 delta 6ins7 mutation. Genetic Testing 3(2):219-221. PMID 10464671. https://pubmed.ncbi.nlm.nih.gov/9758720/
10. Ellis NA, Ciocci S, Proytcheva M, Lennon D, Groden J, German J (1998). The Ashkenazic Jewish Bloom syndrome mutation blmAsh is present in non-Jewish Americans of Spanish ancestry. American Journal of Human Genetics 63(6):1685-1693. PMID 9837821; PMC1377640 — with German J, Sanz MM, Ciocci S, Ye TZ, Ellis NA (2007). Syndrome-causing mutations of the BLM gene in persons in the Bloom’s Syndrome Registry. Human Mutation 28(8):743-753. PMID 17407155. https://pubmed.ncbi.nlm.nih.gov/9837821/
11. MedlinePlus Genetics, US National Library of Medicine (NIH). Bloom syndrome, and the BLM gene — with the NIH Genetic and Rare Diseases Information Center (GARD) entry 915, Bloom syndrome. Retrieved 2026-08-24. https://medlineplus.gov/genetics/condition/bloom-syndrome/ and https://rarediseases.info.nih.gov/diseases/915/bloom-syndrome
12. Bloom Syndrome. StatPearls, NCBI Bookshelf NBK448138 (last update 2023-07-03). https://www.ncbi.nlm.nih.gov/books/NBK448138/
13. US Food and Drug Administration. Device Classification Under Section 513(f)(2) (De Novo): DEN140044, 23andMe Personal Genome Service (PGS); decision granted 2015-02-19; regulation 21 CFR 866.5940; product code PKB — with the FDA Decision Summary for the 23andMe PGS Carrier Screening Test for Bloom Syndrome, the current eCFR text of 21 CFR 866.5940, and an FDA and Health Canada Drug Product Database check for an approved Bloom syndrome therapy (none identified, retrieved 2026-08-24). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?ID=DEN140044
14. National Human Genome Research Institute (NIH). Genetic Discrimination: the Genetic Information Nondiscrimination Act of 2008 (GINA) — what it does and does not protect. Retrieved 2026-08-24. https://www.genome.gov/about-genomics/policy-issues/Genetic-Discrimination
15. Government of Canada, Department of Justice. Genetic Non-Discrimination Act, S.C. 2017, c. 3 (assented to 2017-05-04; consolidation current to 2026-06-21) — with Supreme Court of Canada, Reference re Genetic Non-Discrimination Act, 2020 SCC 17 (judgment of 2020-07-10, docket 38478). https://laws-lois.justice.gc.ca/eng/acts/G-2.5/FullText.html
16. Gregg AR, Aarabi M, Klugman S, et al.; ACMG Professional Practice and Guidelines Committee (2021). Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics. Genetics in Medicine 23:1793-1806 (published 2021-07-20; correction 2021-08-27). https://www.nature.com/articles/s41436-021-01203-z
17. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Colorectal — Version 2.2019 and Version 3.2017, table “Evaluation of CRC Genes Commonly Included on Multi-Gene Panels”, BLM heterozygotes row. https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1436
18. Cunniff C, Bassetti JA, Ellis NA (2017). Bloom’s Syndrome: Clinical Spectrum, Molecular Pathogenesis, and Cancer Predisposition. Molecular Syndromology 8:4-23. PMC5260600. https://pmc.ncbi.nlm.nih.gov/articles/PMC5260600/
19. Bloom Syndrome Registry, Weill Cornell Medicine Department of Pediatrics — cohort description and diagnostic practice, retrieved 2026-08-24 — with a ClinicalTrials.gov (US National Library of Medicine) API v2 condition search for “Bloom Syndrome”, retrieved 2026-08-24 (NCT00021437, observational, completed). https://pediatrics.weill.cornell.edu/research/bloom-syndrome-registry
20. National Society of Genetic Counselors, Find a Genetic Counselor directory (https://findageneticcounselor.nsgc.org/) — Canadian Association of Genetic Counsellors and its public directory (https://genetic-counsellors.ca/) — National Organization for Rare Disorders, Bloom syndrome entry (https://rarediseases.org/rare-diseases/bloom-syndrome/). All confirmed live 2026-08-24.

Last updated: 2026-08-24

Author: Yu Mizuno (Editor-in-Chief, non-physician), GeneLumen editorial team. This article aggregates 20 sources from peer-reviewed medical literature and public health agencies (tier 1=12 / tier 2=8), including NIH resources (MedlinePlus Genetics, GARD, NHGRI), GeneReviews, StatPearls, the FDA, ACMG and NCCN guidelines, Canadian federal statute and Supreme Court sources, and PubMed-indexed publications. Editorial lead: Yu Mizuno, a non-physician research editor.

This article is for educational purposes only and is not a substitute for medical advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. In emergencies, call 911.

Related: Hereditary Cancer category

🌐 日本語版: https://genelumen.com/ja/ja-hereditary-cancer/bloom-syndrome-blm-carrier-cancer-risk-japan